PR Newswire·Nov 12, 2026, 4:05 PM ET

Armata Pharmaceuticals Announces Financial Results for the Third Quarter 2026 and Provides Corporate Update

ARMP

Armata Pharmaceuticals announced third quarter 2026 financial results and corporate updates as of November 12, 2026.
The company is advancing preparations for the pivotal Phase 3 superiority study of AP-SA02 for complicated Staphylococcus aureus bacteremia (SAB), with initiation expected in the second half of 2026 pending FDA protocol concurrence.
FDA granted Breakthrough Therapy designation for AP-SA02, which also holds Fast Track and Qualified Infectious Disease Product designations.
Armata received an additional $3.7 million in non-dilutive funding from the U.S. Department of War (DoW), bringing cumulative DoW funding to approximately $32.4 million for the AP-SA02 program.
Manufacturing progress includes four engineering runs at the Los Angeles cGMP facility, with one clinical production run and vialing completed in the third quarter of 2026.
The company secured FDA agreement on an Initial Pediatric Study Plan for AP-SA02, deferring pediatric studies until adult Phase 3 safety and efficacy data are available.
Grant and award revenue for the quarter ended September 30, 2026, was $3.2 million, up from $1.2 million in the same period in 2025.
Research and development expenses were approximately $6.8 million, while general and administrative expenses were approximately $3.7 million for the quarter.
Net income for the third quarter of 2026 was $54.9 million, or $1.15 per share (basic), driven primarily by a $69.6 million gain from changes in the fair value of the convertible loan.
Loss from operations was approximately $7.4 million for the quarter, compared to a loss of $7.8 million in the prior year period.
Cash and cash equivalents held by Armata as of September 30, 2026, were approximately $18.3 million.
Two new U.S. patents were issued in 2026: one protecting methods for treating S. aureus infections with AP-SA02 until 2041, and another for treating Pseudomonas infections with AP-PA02 until 2043.
Armata presented new data on controlled genetic diversity enhancing S. aureus killing at the 20th International Symposium on Staphylococci and Staphylococcal Infections in September 2026.
As of November 6, 2026, there were 37,192,632 common shares outstanding.

Company: Armata Pharmaceuticals, Inc.
Keywords: Armata Pharmaceuticals, Inc.